The Department of Justice has filed an appeals court brief supporting the right of Medicare officials to negotiate prescription drug prices, a sign that some consumer advocates said suggests the Trump administration is willing to maintain the controversial program.

The Trump administration is moving forward with the defense of a Biden-era plan that allows Medicare to negotiate drug prices against Novartis AG’s appeal at the Third Circuit.

Trump could either weaken the negotiations in a way that benefits the pharmaceutical industry, or try to achieve even deeper savings to outdo his predecessor.

CMS recently issued a statement saying that it's continuing the Medicare Drug Price Negotiation Program but is leaving the door open for potential changes. Experts weighed in on what changes could be made and what changes they would like to see.

The Centers for Medicare and Medicaid Services (CMS) and pharmaceutical drug manufacturers are gearing up for the second round of negotiations as

The federal health insurance program has selected 15 additional drugs covered by Medicare Part D for its next round of price negotiations, the Centers for Medicare & Medicaid Serv

The start of Donald Trump’s second presidency and Republican control in the 119th Congress raises questions about the future of the IRA’s

President Donald Trump will meet with major drugmakers' executives to discuss drug pricing and insurance changes. Key topics include Medicare price negotiations, pharmacy benefit management, and potential tariffs on pharmaceuticals.

The industry is also pushing for curbs on the rebates they pay pharmacy benefit managers, which act as middlemen between drug companies and consumers, in exchange for favorable pl